The PENNANT Study

The purpose of the PENNANT clinical study is to evaluate the safety, tolerability, and effectiveness of the study drug (H.P. Acthar Gel®) in slowing the loss of motor skills or brain function in patients with ALS and to assess whether the study drug can increase an ALS patient’s life expectancy.  Eligible participants will either receive the study drug or a placebo (inactive drug).

Official Title: A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects with Amyotrophic Lateral Sclerosis

Read more at ClinicalTrials.gov

You may qualify for the study if:*

  • You are between the ages of 18 and 75 years old (inclusive) at your first study visit
  • You have a documented diagnosis of ALS
  • Your ALS symptoms began no more than 2 years prior to your first study visit
  • You do not have diabetes or high blood pressure
  • You are able and willing to receive daily injections of study product under your skin

 

* Additional requirements will apply. All study potential study participants will be screened by a trained physician to determine eligibility.

What is involved if I participate?

  • Volunteers will be in the study for approximately 47 weeks.
  • Volunteers will visit the clinic at least 12 times and complete 1 telephone call
  • All study visits will occur at UCSF’s Parnassus campus.
  • If you choose to volunteer and pass several screening tests, you will be randomly assigned to either H.P. Acthar Gel® (active drug) or a placebo (inactive drug).
  • You will inject your assigned study drug once daily. After each injection, you will also fill out a short questionnaire on a study-provided mobile device.
  • If the study doctor decides it is in your best interest to continue, you will be offered an additional 48 weeks of treatment with the study drug and visit the clinic approximately 5 more times.

 

If you are interested in participating or want to learn more, please contact the study coordinator Theresa Devine at 415-502-1672 or Theresa.Devine@ucsf.edu.